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Background: To examine the differences of associated characteristics and prescription drug use between co-occurring
unipolar and bipolar disorders in patients with eating disorders (EDs).
Methods: Patients with EDs and major depressive episode (MDE) were recruited from psychiatric outpatient clinics. They
were interviewed and completed self-administered measures assessing eating and general psychopathology. The
prescribed drugs at the index outpatient visit were recorded. Clinical characteristics and prescription drugs of groups with
major depressive disorder (ED-MDD), MDE with lifetime mania (ED-BP I), and MDE with lifetime hypomania (ED-BP II) were
compared. Continuous variables between groups were compared using generalized linear regression with adjustments of
age, gender, and ED subtype for pair-wise comparisons. Multivariate logistic regression with adjustments of age, gender,
and ED subtype was employed to estimate adjusted odds ratios with 95% confidence intervals between groups.
Results: Two hundred and twenty-seven patients with EDs had a current MDE. Among them, 17.2% and 24.2%
experienced associated manic and hypomanic episodes, respectively. Bipolar I and II patients displayed significantly
poorer weight regulation, more severe impulsivity and emotional lability, and higher rates of co-occurring alcohol use
disorders than ED-MDD patients. ED-BP I patients were found to have the lowest IQ, poorest working memory, and the
most severe depression, suicidality and functional impairment among all patients. Patients with ED-BP II shared affect and
behavioral dysregulations with ED-BP I, but had less severe degrees of cognitive and functional impairments than ED-BP I.
Patients with ED-BP I were significantly less likely than those in the ED-MDD and ED-BP II groups to be on antidepressant
monotherapy, but a great rate (27%) of ED-BP I individuals taking antidepressant monotherapy had potential risk of mood
switch during the course of treatment.
Conclusions: Our study identified discriminative features of bipolar I and II disorders from MDD among a group of
depressed ED patients. We suggest that the associated mania, hypomania, and mood lability are predictors of clinical
severity and should be identified from ED patients presented with depressive features. Accurate diagnosis of bipolar
disorders may have implications for pharmacotherapy in patients with EDs.
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The relationship between affective disorders and eating
disorders (EDs) has been well documented [1], but much
of the research focuses exclusively on major depressive
disorder (MDD) and EDs. Eating disorders, having high
co-morbid rates of psychiatric and physical disorders,
have been conceptualized as having features overlapping
with bipolar spectrum disorders [2, 3], more specifically
between binge-eating related disorder and bipolar II
disorder [4–6]. Studies reveal that lifetime prevalence of
bipolar disorders in the ED population ranges from 0%
to 34.8% in community or outpatient samples [7, 8], and
36% to 64% among inpatients [9, 10]. A few papers using
diagnostic questionnaire or symptom scale have found a
rate of 19% bipolar II in individuals with EDs and higher
hypomania scores in individuals with binge-eating dis-
order (BED) than subthreshold BED [11, 12]. Several
studies have investigated the correlates of EDs in
patients with bipolar disorders [13–16], far fewer have
examined the effects of bipolar disorder on patients with
EDs [6, 8]. No studies have examined the discriminative
effects of bipolar I and bipolar II disorders from MDD
in patients with EDs. Recent studies adopting the Diag-
nostic and Statistical Manual of Mental Disorders, 5th
Edition(DSM-5)’s [17] broadened criteria of EDs have
further substantiated their relationship [6, 18].
Individuals were classified as having lifetime bipolar I
disorder if they had ever had a manic episode, defined as a
period of seven days or longer with elevated mood, and
three other mania symptoms, or with irritable mood plus
four other mania symptoms, with the mood disturbance
resulting in marked impairment, or hospitalization. Individ-
uals were classified as having lifetime bipolar II disorder if
they had had both major depressive episodes (MDEs) and a
hypomanic episode, defined by a period of four days or
longer with symptom criteria similar to mania, and with an
unequivocal change in function, but without a manic
episode [19]. In a few other studies, concerns regarding
diagnosing individuals with major depression who have a
history or concomitant hypomania/mania were addressed
(bipolar depression) [20–22]. Bipolar disorders are highly
prevalent in clinical samples of depressed patients, with bi-
polar I disorder being diagnosed in 18− 47.1% of cases, and
bipolar II disorder in 7.7 − 45% [23, 24]. Compared with in-
dividuals with only major depression (unipolar depression),
those with major depression and subthreshold mania/hypo-
mania were found to have significantly higher rates of panic
disorder, alcohol use disorders, and behavioral problems
[25, 26]. Individuals with bipolar II disorder had even
higher rates of anxiety disorders and behavioral problems
than those with major depression and subthreshold mania/
hypomania [26].
Bipolar II disorder is defined as a milder form of bipolar
disorder with regard to hypomanic symptom intensity[17]. However, compared to individuals with bipolar I
disorder, individuals with bipolar II disorder may have
greater chronicity of illness and spend more time in the
depressive phase of their illness [27, 28]. Some researchers
have found patterns of comorbidity [15, 29], suicide
attempts [14, 30], and functional impairments [31] in
bipolar II disorder that are equivalent to those in bipolar I
disorder, but others report higher rates of psychiatric co-
morbidity [30, 32] and suicide attempts [32] in bipolar II
compared to bipolar I disorder. Variability in psychiatric
comorbidity and functional impairments in bipolar disor-
ders could be related to clinical heterogeneity in sample
composition and index illness phase [15, 28].
The evidence of efficacy of drug treatments for EDs
has been mostly weak or moderate [33]. Fluoxetine (a
selective serotonin reuptake inhibitor) remains to be the
only drug approved for bulimia nervosa (BN) until Lis-
dexamphetamine dimesylate was approved for BED by
the US Food and Drug Administration in 2015 [34].
Close monitoring for emergence of hypomanic/manic
symptoms is suggested when antidepressant monother-
apy is utilized in the treatment of individuals with bipo-
lar depression [35]. Differentiating bipolar I and bipolar
II disorders from MDD in ED patients with clinical pre-
sentations of major depression is therefore critical for
pharmacological treatment.
Based on the above reviews, we hypothesized that de-
pressed ED patients with comorbid bipolar I and bipolar
II disorders had differential features from patients with
comorbid MDD and those with comorbid bipolar I and
II disorders were under-treated with drugs other than
antidepressants. This study aimed to examine the associ-
ated features between co-occurring bipolar and unipolar
disorders in depressed ED patients. We stratify bipolar
disorders into bipolar I and bipolar II considering they
may have different associated features from unipolar de-
pression. Moreover, we examined the differences of pre-
scription drugs between the three groups of depressed
ED patients in clinical practice.
Methods
Participants and procedures
Participants were selected from a group of ED patients
(n = 288) who were enrolled upon their first visit to the
general psychiatric clinics at a teaching hospital via a
two-phase method between August 2010 and July 2014
[6]. The written informed consent was obtained from the
patients before enrollment. Individuals with active psychotic
symptoms, mental sub-normality, organic mental condi-
tions, and severe medical illnesses were excluded. All study
participants were ED patients with current MDE, and were
diagnosed by the ED module of the Structured Clinical
Interview for DSM-IV-TR Axis I disorders Patient version
(SCID-I/P) [36] and Mini International Neuropsychiatric
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views, assessing comorbid psychiatric diagnoses, history of
self-injury behaviors or suicide attempts, and functional
impairment. Diagnostic raters were one psychiatrist and two
highly trained research assistants with degrees in psych-
ology, who were monitored throughout the study to
minimize rater drift. Participants underwent intelligence
testing, and completed several questionnaires concerning
eating pathology, affect lability, and impulsivity. The drugs
prescribed at this index visit were recorded. The Institu-




An ED diagnosis in the last three months and further in
the past was established using the SCID-I/P, and adapted
to meet the criteria of the DSM-5. Female patients were
not required to meet the criteria of amenorrhea for
anorexia nervosa (AN). The minimum frequency and
duration of binge-eating/purging was once per week for
three months for BN and BED [17]. Participants who re-
ported extreme weight or shape concerns, less frequent
yet regular binge-eating symptoms, or binge-eating with-
out feelings of distress, and those who did not meet
other criteria for the previous disorders, were diagnosed
with ED, not otherwise specified (EDNOS).
MINI
The MINI is a short, diagnostic interview for the DSM-IV
and ICD-10 psychiatric disorders [37]. It is divided into
modules, including diagnoses of major depression, bipolar
disorders, anxiety disorders, and alcohol/substance use
disorders. The first 40 participant interviews were audio-
taped. The κ coefficients of inter-rater reliability for all
diagnoses fell between .60 (social phobia) and 1.00 (major
depressive episode), except that for substance use disorder
(.47). We used the MINI to assess comorbid Axis I psychi-
atric disorders.
Assessment of functional impairment and suicide risks
The 87-item Structured Interview for Anorexic and Bulimic
Disorders, Expert-Assessment (SIAB-EX) covers a wide range
of symptoms frequently seen in EDs — body image distur-
bances, bulimic symptoms, social integration problems, prob-
lems associated with sexuality, depression, compulsion, and
anxiety [38]. Each item was rated for present status (the last
three months) and for maximum pathology in previous years
(lifetime). Responses were rated on a severity scale, ranging
from 0 for “symptom not present” to 4 for “symptom very
much/very severely present”. Following an independent, pro-
fessional translation of the Chinese version of the SIAB-EX,
all items were reviewed by two psychiatrists. The assessment
of functional impairment was adopted from item 53, “wasyour work performance objectively impaired at work or in
your household?” Suicide risks were rated by item 69, “did
you ever attempt to commit suicide?”, and item 70, “did you
ever hurt yourself intentionally?” Severity of suicidal acts and
auto-aggressive behaviors was rated according to the number
of attempts or seriousness of physical injury. Inter-rater reli-
ability (κ coefficient) for present and lifetime severity of item
53 was .76 and .74, respectively, and ranged from .53− .78
for items 69 and 70 [39].Intelligence quotient and working memory assessments
In this study, we used the short form of Wechsler Adult
Intelligence Scale—Third Edition (WAIS–III) to assess
the intelligence quotient in the groups. It comprises four
subtests (Similarities, Matrix Reasoning, Arithmetic, and
Digit Symbol substitution) and has been demonstrated
to exceed other subtest combinations with respect to
validity, content representation, and time saving [40].
This short form AIS-III has been used in several studies
on patients with neuropsychiatric disorders [41–43].
Scores of working memory were summed by Arithmetic
and Digit Span, and were converted to the estimated
percentile rank according to the Taiwanese norm [44].Bulimic Investigatory Test Edinburgh (BITE)
This self-reported measure includes the Symptom Scale (30
items) and the Severity Scale (6 items). The Chinese BITE
has good internal consistency (Cronbach’s α= .78 and .52,
respectively) and test-retest reliability (intra-class correlation
reliability of .86 and .88, respectively) for the two scales [45].Body Shape Questionnaire (BSQ)
The BSQ was initially developed as a 34-item question-
naire for assessing feelings about body shape, and the
behavioral and emotional consequences of such feelings.
The BSQ-8 used in this study, which has 8 items derived
from the Chinese BSQ-34 [46] has good internal
consistency (Cronbach’s alpha, α = .88).Affect Lability Scale (ALS)
This study adopted an 18-item short form (ALS-18) that
was established by selecting items from the original 54-
item ALS using exploratory factor analysis with eigen-
values greater than 1 [47]. The original ALS assesses
people’s endorsements regarding the tendency of their
mood to shift between what they consider normal, to the
affective domains of anger, depression, elation, and anx-
iety, as well as their tendency to oscillate between depres-
sion and elation, and between depression and anxiety [48].
The reliability test showed excellent internal consistency
for the Chinese version of the ALS-18 (Cronbach’s α
= .93) and item-total correlations ranged from .37 to .76.
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The BDI is a 21-item measure examining depressive
symptom severity over the last week. Each question has at
least four response options of differing intensities. A value
ranging 0–3 is assigned to each answer and the total score
determines depression severity. The Chinese version of
the BDI has shown good reliability and construct validity
[49]. and showed good internal consistency in this study
(Cronbach’s α = .91).
Barratt Impulsiveness Scale (BIS)
This is a 30-item self-report questionnaire measuring
trait impulsivity [50]. The Chinese version of BIS-11
(BIS-11-CH) is modified from the original BIS by re-
moving five items (item 15, 21, 23, 27, and 29) with poor
item-total correlations (less than .1) [51]. The remaining
25 items of the BIS-11-CH had a Cronbach’s α of .83,
and an intact factorial structure of inability to plan (fac-
tor 1), lack of perseverance and self-control (factor 2),
and propensity toward novelty-seeking and acting with-
out thinking (factor 3) [51].
Statistical analysis
Clinical and demographic characteristics of groups with
MDD (ED-MDD), MDE with lifetime hypomanic episodes
(ED-BP II), and MDE with lifetime manic episodes (ED-BP
I) were compared. Descriptive statistics were computed to
determine means and standard deviations of all continuous
variables and frequency distributions for categorical vari-
ables. The differences of demographic data between groups
were compared using ANOVA and Chi-square tests for
continuous variables and categorical variables, respectively.
With apparent differences in the distribution of gender and
ED subtypes in different comorbid groups, multivariate
analyses were therefore applied. Continuous variables
between groups were compared using generalized linearTable 1 Comparison of demographics and clinical variables for eatin
Variables Eating disorders with
MDD (n = 133)
Eatin
disor
Gender, female (N, %) 124 (93.2) 46 (8
Age (years) 27.3 ± 7.4 28.2
Age at onset of disordered eating (years) 20.3 ± 6.3 19.2
Age at onset of depression (years) 22.8 ± 6.9 22.2
Education (years) 14.4 ± 2.3 15.0
Eating disorder subtypes (N, %)
Anorexia Nervosa 32 (24.1) 4 (7.
Bulimia Nervosa 60 (45.1) 25 (4
Binge eating Disorders 25 (18.8) 19 (3
Eating disorders NOS 16 (12.0) 7 (12
Values in bold type indicated statistically significant
MDD major depressive disorder
Values indicate N (%) or Mean ± SDregression with adjustments of age, gender, and ED subtype
for pair-wise comparisons. Multivariate logistic regression
with adjustments of age, gender, and ED subtype was
employed to estimate adjusted odds ratios (AORs) with
95% confidence intervals (CIs) between groups. Since there
were four subtypes in ED patients, three dummy variables
were involved in the regression model. All tests were two-
tailed, and p < .05 was considered significant. All statistical
analyses were performed using SAS, version 9.4 (Cary,
North Carolina, USA).
Results
Demographics and clinical characteristics
Among the ED patients, 227 were diagnosed to have a
current MDE. Patients who had current MDE had a later
age of onset of ED compared to those who did not have
(20.1 ± 6.3 vs. 18.1 ± 4.3). There were no differences of age,
gender, and educational levels between the two groups.
Table 1 shows the comparison of demographics and distri-
bution of ED subtypes between ED-MDD (58.6%), ED-BP II
(24.2%), and ED-BP I (17.2%). No statistically significant
differences in age, age at ED onset, and age at depression
onset, were observed between groups. Patients with ED-BP
I had the lowest educational level among all. The diagnostic
distribution of AN, BN, BED, and EDNOS was 41 (18.1%),
101 (44.5%), 58 (25.6%), and 27 (11.9%), respectively. ED-BP
I and ED-BP II comprised of higher percentages of BN and
BED patients. There were statistically significant differences
of sex distribution, age, age of onset of disordered eating,
and BMI among ED subtypes (Additional file 1: Table S1.1).
There was less female predominance in BED group com-
pared to AN and BN groups. Age differences only existed
between BED and BN patients that patients with BED were
significantly older and had a later age of onset of eating
problems than patients with BN. Patients with BED were
the heaviest among all for both current and previous bodyg disorder patients during major depressive episodes
g disorders with bipolar II
der (n = 55)
Eating disorders with bipolar I
disorder (n = 39)
P-value
3.6) 31 (79.5) 0.0254
± 7.2 28.4 ± 8.8 0.6184
± 4.4 20.4 ± 8.1 0.5211
± 6.7 21.4 ± 8.0 0.6032
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level was observed among ED subgroups. However, other
EDs had significantly higher risks of association with gener-
alized anxiety disorder, social phobia, panic disorders, agora-
phobia and alcohol use disorder than AN but showed
comparable risks of association with most psychiatric disor-
ders between themselves (Additional file 1: Table S1.2).
Severity of psychopathology and psychiatric comorbidity
Information concerning clinical correlates of the ED with
different affective disorders adjusting with sex, age, and ED
subtypes is presented in Tables 2 and 3. Patients with ED-
BP I had the lowest intelligence quotient and working
memory score among all. Compared to the ED-MDD
group, those with ED-BP I/BP II had statistically signifi-
cantly severe degrees of mood lability and impulsiveness,
higher current body weight and binge-eating/purging
severity. Moreover, patients with ED-BP I/BP II also had a
significantly higher rate of comorbidity with alcohol use
disorders than ED-MDD patients. Patients with ED-BP I
also had a two-fold higher co-occurrence rate of panic dis-
order than patients with ED-MDD. In comparison to ED-
MDD and ED-BP II patients, patients with ED-BP I had
more severe depression, mood lability and a greater rate of
severe role impairments. The proportion of patients with
ED-BP II who had attempted suicide (29%) fell between
that of the bipolar I and MDD groups (36% and 17%,
respectively). Only the difference between the latter two







(n = 133) (n = 55)
Mean ± SD Mean ± SD
Intelligence quotient 101.2 ± 13.7 100.9 ± 12.7
Working memory 54.9 ± 26.5 54.6 ± 29.2
Bulimic Investigatory Test Edinburgh 29.7 ± 11.6 31.8 ± 9.1
Symptom subscale 20.4 ± 6.4 21.3 ± 5.4
Severity subscale 9.3 ± 6.6 10.5 ± 5.1
Body Shape Questionnaire-8 4.6 ± 1.2 4.9 ± 1.1
Beck Depression Inventory 26.2 ± 10.6 26.8 ± 8.8
Affective Lability Scale 48.3 ± 8.7 51.6 ± 7.9
Barrett Impulsiveness Scale 58.5 ± 6.0 61.6 ± 6.9
BMI, current (kg/m2) 20.3 ± 4.8 23.5 ± 5.5
BMI, maximal (kg/m2) 23.8 ± 5.1 26.8 ± 6.4
BMI, minimal (kg/m2) 17.0 ± 3.2 18.7 ± 2.9
Values in bold type indicated statistically significant
MDD major depressive disorder, BMI Body mass index
†adjusted for age, gender, and eating disorder subtypesdistinct features of psychiatric co-morbidities from other
EDs, we re-analyzed the data after excluding patients with
AN. Significant differences of affective lability and current
body weight between ED-MDD and ED-BP II group no
longer existed and there were no significant difference of
percentage of suicidal acts between groups (Additional file
2: Table S2.1 − 2.4). We also provide Additional file 3: Table
S3.1− 3.3 to show the comparison of psychiatric co-
morbidity in different ED subtype patients with three
groups of affective disorders. Of note, small sample size in
some co-morbidity categories may cause difficulties or in-
stability in estimation of statistical significance.
Pharmacotherapy among different groups
Antidepressants were the most frequently prescribed
medication (63.0%), either as monotherapy (44.9%) or
concomitantly with other drugs, for ED patients with a
current MDE (Table 4). The percentage of patients
prescribed antidepressant monotherapy in ED-BP I and
ED-BP II was statistically significantly different from
ED-MDD groups. Although ED-BP I patients were sig-
nificantly less likely than those in the ED-MDD (AOR=
0.35, 95% CI = 0.15 − 0.83, p = .017) and ED-BP II (AOR =
0.28, 95% CI = 0.11 − 0.72, p = .008) groups to be on anti-
depressant monotherapy, a great rate of ED-BP I
individuals taking antidepressant monotherapy (27%) was
exposed to the risk of mood switch during the course of
treatment. The second most commonly prescribed





2 vs. 1 3 vs. 1 3 vs. 2
(3)
(n = 39)
Mean ± SD P-value† P-value† P-value†
93.0 ± 14.6 0.6897 0.0085 0.0070
36.4 ± 27.7 0.8742 0.0003 0.0026
30.4 ± 11.7 0.0695 0.3315 0.4221
19.4 ± 6.3 0.2238 0.5335 0.0760
10.9 ± 7.3 0.0612 0.0334 0.7174
4.4 ± 1.3 0.0870 0.5152 0.0465
31.7 ± 9.5 0.9275 0.0079 0.0125
56.7 ± 8.6 0.0410 <0.0001 0.0039
62.4 ± 6.9 0.0018 0.0006 0.5505
23.6 ± 6.2 0.0488 0.0430 0.8204
25.7 ± 5.4 0.0243 0.4736 0.3549
18.5 ± 3.8 0.2187 0.3413 0.8838








2 vs. 1 3 vs. 1 3 vs. 2
(1) (2) (3)
(n = 133) (n = 55) (n = 39)




50 (37.6) 27 (49.1) 20 (51.3) 1.31 (0.68, 2.54) 1.50 (0.71, 3.17) 1.17 (0.49, 2.79)
Social phobia 46 (34.6) 23 (41.8) 18 (46.2) 1.29 (0.65, 2.55) 1.63 (0.76, 3.50) 1.21 (0.52, 2.82)
Panic disorder 16 (12.0) 14 (25.5) 12 (30.8) 2.02 (0.89, 4.60) 2.73 (1.12, 6.69) 1.47 (0.56, 3.80)
Agoraphobia 27 (20.3) 13 (23.6) 15 (38.5) 0.97 (0.44, 2.11) 2.14(0.95, 4.83) 2.25 (0.87, 5.83)
Obsessive compulsive
disorder
38 (28.6) 19 (34.6) 17 (43.6) 1.23 (0.61, 2.47) 1.80 (0.84, 3.85) 1.52 (0.64, 3.60)
Post-traumatic stress
disorder
15 (11.3) 22 (20.0) 5 (12.8) 1.79 (0.74, 4.33) 1.13 (0.37, 3.44) 0.59 (0.18, 1.89)
Alcohol abuse/
dependence
5 (3.8) 12 (21.8) 12 (30.8) 7.68 (2.41, 24.44) 14.55 (4.37, 48.41) 2.05 (0.74, 5.70)
Drug abuse/
dependence
23 (17.3) 10 (18.2) 10 (25.6) 1.15 (0.49, 2.69) 1.67 (0.69, 4.06) 1.48 (0.53, 4.09)
Functional impairmentb 0.87 (0.45, 1.68)a 4.46 (1.80, 11.04)a 5.11 (1.91, 13.72)a
Severe and very
severe
67 (50.4) 26 (47.3) 32 (82.1)
Marked 45 (33.8) 18 (32.7) 7 (18.0)
None and mild 21 (15.8) 11 (20.0) 0
Suicide actsc 23 (17.3) 16 (29.1) 14 (35.9) 1.72 (0.80, 3.70) 2.52 (1.10, 5.77) 1.39 (0.57, 3.40)
Auto-aggressive
behaviorsd
41 (30.8) 15 (27.3) 18 (46.2) 0.81 (0.39, 1.67) 1.92 (0.89, 4.11) 2.18 (0.89, 5.37)
AOR: odd ratio adjusted for age, gender, and eating disorder subtypes
Values in bold type indicated statistically significant
MDD major depressive disorder
Impairments and suicide were assessed using the Structured Interview on Anorexic and Bulimic Disorder, Expert-Assessment (SIAB-EX)
aPatients with severe and very severe impairments compared with all others
b: rated by the Item 53 ‘Was your work performance objectively impaired at work or in your household ?”. Severity of impairment is rated from 0 (=no) to 4
(=very severe)
c: rated by the item 69 ‘Did you ever attempt to commit suicide?’
d: rated by the Item 70 ‘Did you ever hurt yourself intentionally?’. Severity of suicidal acts and auto-aggressive behaviors is rated from 0 (= symptom not present)
to 4 (= symptom very much/very severely present) according to the number of attempts or seriousness of physical injury; here suicide acts indicated the severity
more than one serious attempt or many minor attempts and auto-aggressive behaviors indicated the severity more than marked degree
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sants and atypical antipsychotics (15.9%). Patients with
ED-BP I disorder were more likely to be taking atypical
antipsychotics than those with ED-BP II disorder, and
were also more likely to be taking mood stabilizers and
less likely to be taking antidepressants than those with
ED-MDD. No differences presented in other comparisons
between groups.
Discussion
Using structured interviews and self-administered question-
naires, we found that lifetime hypomania and mania were
prevalent in ED patients with a current MDE, with bipolar I
disorder being diagnosed in 17.2% and bipolar II in 24.2% of
patients. There were varying associated psychopathologyacross groups with different comorbidities. ED-BP I and ED-
BP II patients tended to have a greater body weight and
increased suicidality, greater affect lability, impulsiveness, and
a higher rate of alcohol use disorder than ED-MDD patients.
Patients with ED-BP I reported the most severe binge-eating,
depression, affect lability, impaired intelligence and working
memory, and lifetime functional impairments. Although
patients with ED-BP I had statistically significantly severe
degrees of impulsiveness and higher co-occurrence rates of
panic disorder and alcohol use disorder than patients with
ED-MDD, they did not differ from patients with ED-BP II in
these dimensions. Twenty-seven percent of ED-BP I patients
were treated with antidepressant monotherapy that left this
subgroup of patients unprotected from future mood switch
and increased likelihood of chronicity of illness.








2 vs. 1 3 vs. 1 3 vs. 2
(1) (2) (3)
(n = 133) (n = 55) (n = 39)
N (%) N (%) N (%) AOR (95% CI) AOR (95% CI) AOR (95% CI)
Antidepressant
monotherapy
61 (48.0) 31 (56.4) 10 (27.0) 1.23 (0.62, 2.42) 0.35 (0.15, 0.83) 0.28 (0.11, 0.72)
mood stabilizer
monotherapy
0 1 (1.8) 0 NA NA NA
Atypical antipsychotic
monotherapy
32 (25.2) 6 (10.9) 9 (24.3) 0.41 (0.15, 1.09) 1.04 (0.41, 2.61) 2.65 (0.82, 8.59)
Antidepressant plus
mood stabilizers
1 (0.8) 0 1 (2.7) NA NA NA
Antidepressant plus
antipsychotic




1 (0.8) 1 (1.8) 1 (2.7) 2.26 (0.13,
39.12)
4.00 (0.23, 68.78) 1.78 (0.10, 30.80)
Any antidepressant 80 (63.0) 42 (76.4) 21 (56.8) 1.70 (0.78, 3.72) 0.70 (0.31, 1.60) 0.38 (0.15, 0.99)
Any mood stabilizer 5 (3.9) 3 (5.5) 6 (16.2) 1.01 (0.25, 4.88) 3.95 (1.06, 14.71) 3.96 (0.90, 17.44)
Any atypical antipsychotic 51 (40.2) 17 (30.9) 21 (56.8) 0.72 (0.36, 1.47) 2.13 (0.97, 4.65) 2.92 (1.18, 7.20)
MDD major depressive disorder
Data mission for 6 and 2 persons in eating disorders with MDD and eating disorders with bipolar I disorder, respectively
AOR: odd ratio adjusted for age, gender, and eating disorder subtypes
Values in bold type indicated statistically significant
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ED patients with a current MDE. Anxiety, impulsivity,
suicide attempts, and alcohol/drug use disorders are pre-
vailing comorbidities observed in ED patients [5, 52–54].
Our study found that ED-BP I patients had a two-fold
higher rate of comorbidity with panic disorder and ED-BP
I and ED-BP II patients had a higher rate of comorbidity
with alcohol use disorders (14- and 7-fold, respectively)
compared to those with ED-MDD. This observation was
consistent with prior findings that individuals with bipolar
spectrum disorders had significantly higher rates of many
psychiatric disorders, including panic disorder and alcohol
use disorders [31]. It is noteworthy that prior suicide
attempts were reported by approximately 30% of our ED
patients with bipolar I and bipolar II disorders and that
the suicide risk was two-fold higher in this population
compared to ED patients with comorbid MDD. These
findings were in line with two earlier studies reporting
that suicidal or self-destructive behavior in ED patients is
associated with bipolar disorder [55, 56]. The presence of
EDs has been implicated as a marker of clinical severity in
patients with bipolar disorders, including more frequent
suicide attempts than among those without EDs [13, 14,
57]. The co-existence of EDs and bipolar disorders,
especially bipolar I, indicates greater risks of suicide and
psychiatric comorbidity in both groups of patients.It is interesting to notice that heterogeneity also existed
between patients with ED-BP I and ED-BP II when
compared to those with ED-MDD. Patients with ED-BP II
appeared to share affect and behavioral dysregulations with
ED-BP I, but did not have as severe degrees of cognitive
and functional impairments as ED-BP I. This finding added
more evidence to support earlier concerns that failure to
recognize the history or co-existence of hypomania symp-
toms in patients with MDE might result in no or corres-
pondingly inadequate treatment as discussed as follows.
Although the benefits of antidepressant monotherapy re-
main unclear in the treatment of bipolar depression [35], it
is the most common initial prescription in all ED patients
with a current MDE. Patients with ED-bipolar II had a
comparable rate of being prescribed antidepressant mono-
therapy with patients with ED-MDD, and were more likely
currently taking antidepressants monotherapy than patients
with ED-bipolar I, leaving the concern that patients with
hypomania might be less likely than those with mania to be
identified from patients with MDEs or they had received
adequate treatment for associated problems by taking anti-
depressants monotherapy. Antidepressant monotherapy
may, however, expose ED patients with comorbid bipolar
spectrum disorders to a potentially increased risk of mood
lability and poor impulse control, among other dangerous
consequences. There is a growing consensus from experts
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tients with bipolar I disorder, patients with bipolar depres-
sion with two or more concomitant manic symptoms, and
in bipolar patients with high mood instability or with a his-
tory of rapid cycling [35, 58]. Several researchers have ad-
dressed the role of affect lability or hypomania symptoms
in binge-eating behaviors or other impulsive behaviors in
ED patients [12, 59]. With comparison to the recognition
of history of mania, hypomania, or mixed episodes, mood
lability may be a more obvious indicator to avoid anti-
depressant monotherapy.
Several open series studies [60] or double-blind placebo-
controlled studies [61–63] have demonstrated that atypical
antipsychotics, e.g. olanzapine and quetiapine, have efficacy
in reducing depressive or obsessive symptoms and causing
weight gain in patients with AN. However, studies examin-
ing the efficacy of atypical antipsychotics in reducing
binge-eating in patients with BN are scarce. Use of atypical
antipsychotics in the treatment of EDs was not uncommon
among our patients (40.2%− 56.8%). Although meta-
analysis studies have yielded disappointing result [64], it is
believed that some ED patients might benefit from anti-
psychotic medication [33, 65, 66]. Mood stabilizers have not
had a large role in the treatment of EDs and topiramate (an
anticonvulsant) had well-established efficacy in reducing
binge-eating frequency and weight loss [67]. Both were not
used frequently in our sample. Our results provide support
for the rationale of the use of antipsychotics or mood stabi-
lizers in the treatment of ED patients if comorbid bipolar
disorders can be identified via the recognition of associated
features reported in this present study. We hypothesize that
treatment effects on affect lability and impulsivity might
offset adverse effects of weight gain by taking antipsychotics
or mood stabilizers and are beneficial for eating and weight
control in a subgroup of ED patients with co-occurring
bipolar disorders. However, further work to determine the
indication and efficacy of atypical antipsychotics or mood
stabilizers in the treatment of EDs is merited.
This study did have a few methodological limitations.
The first was the small sample size. Consequently, all types
of EDs were grouped together. Different ED subtypes may
have different risks of association with psychiatric morbid-
ities that would have influences on our current findings.
Second, participants were selected in a tertiary center in a
non-Western country, and thus, the sample may not be
representative of the population with EDs elsewhere. Third,
the medication use reported in this study was per psychia-
trists’ prescriptions from their initial encounters with
patients. We did not follow up any changes in prescription
at subsequent visits, or check patients’ compliance in taking
these medications. Finally, this is a cross-sectional design,
and diagnosis of lifetime hypomania/mania was per
patients’ self-reports. Recall bias may exist. In spite of these
limitations, to our knowledge, this is a pioneering work,examining the influence of bipolar disorders on ED patients
during MDEs. It has important implications for pharmaco-
therapy in the management of ED.Conclusions
Our study identified discriminative features of bipolar I
and II disorders from MDD among a group of depressed
ED patients. It is critical to recognize the presence of
mood lability, a history of hypomanic/manic episodes, and
other features associated with bipolar disorders, to evalu-
ate if individuals with major depression may have hidden
bipolarity. The co-occurrence of bipolar disorders in ED
patients may provide clues indicating disease severity and
the likelihood of presentation of impulsiveness, suicidality,
psychiatric comorbidities, and even cognitive and func-
tional impairments. The use of antidepressants in patients
with EDs should be considered carefully if they have co-
existent dysregulated mood and behavioral symptoms.Additional files
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